Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Katz, Alan ^a   Ferrer, Montserrat ^b,c,d   Suárez, José F ^e   Alonso, Jordi ^b   Becerra, Adela Virginia ^b   Cunillera, Oriol ^b   Garín, Olatz ^b   Pardo, Yolanda ^b   Pont, Angels ^b   Boladeras, Ana ^f   Ferrer, Ferran ^f   Guedea, Ferran ^f   Martínez, Evelyn ^f   Padin, Victoria Eugenia ^f   Pera, Joan ^f   Ventura, Montse ^f   Aguiló, Ferran ^e   Pastor, Sergio ^g   Prats, Josep Maria ^g   de León, Javier Ponce ^h   Villavicencio, Humberto ^h   Batista, Jose Emilio ⁱ   Craven Bratle, Jordi ^j   Sancho, Gemma ^j   Ayala, Adriana ^k   de Paula, Belen ^k   Fernández, Pablo ^k   Guix, Benjamin ^l   Herruzo, Ismael ^m   Hernández, Helena ⁿ   Muñoz, Víctor ⁿ   Hervas, Asunción ^o   Ramos, Alfredo ^o   Macias, Víctor ^p   Solé, Josep ^q   Bonet, Marta ^q   Marcos, Pilar ^r   Mariño, Alfonso ^s   Ortiz, María José ^t   Prada, Pedro J ^u   more..

^a Flushing Radiation Oncology   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g Institut Català d'Oncologia ^*  (Spain)

^h FUNDACIÓ PUIGVERT   (Spain)

ⁱ Fundacion Teknon   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k Instituto Oncologico de Guipuzcoa   (Spain)

^l Fundacion IMOR   (Spain)

^m Hospital Regional Carlos Haya   (Spain)

ⁿ Hospital Meixoeiro Complejo CHUVI   (Spain)

^o HOSPITAL RAMÓN Y CAJAL   (Spain)

^p Hospital Cínico Universitario de Salamaca   (Spain)

^q Institut Oncologic del Valles IOV   (Spain)

^r HOSPITAL GENERAL DE CATALUNYA   (Spain)

^s Centro Oncologico de Galicia   (Spain)

^t HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^u HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

Prostate cancer; Prostatectomy; Quality of life; Stereotactic body radiotherapy

Indexed keywords

AMIFOSTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY CANCER; HUMAN; INTESTINE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SEXUALITY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT DURATION; URINARY TRACT;

ADENOCARCINOMA; ADULT; AGED; FOLLOW-UP STUDIES; HUMANS; INTESTINAL DISEASES; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOSURGERY; RETROSPECTIVE STUDIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 84869171326     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-194     Document Type: Article

References (46)

1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998, 280:969-974. 10.1001/jama.280.11.969, 9749478.
2. Klein EA. Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view. Semin Radiat Oncol 1998, 8:87-94. 10.1016/S1053-4296(98)80004-0, 9516589.
3. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3. 10.1186/1748-717X-6-3, 3022740, 21219625.
4. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8:387-392.
5. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1. 10.1186/1471-2490-10-1, 2831888, 20122161.
6. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048. 10.1016/j.ijrobp.2008.05.059, 18755555.
7. Klotz L. Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Urol Rep 2012, 13:153-159. 10.1007/s11934-012-0242-4, 22477615.
8. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213. 10.1056/NEJMoa1113162, 3429335, 22808955.
9. Ferrer M, Suarez JF, Guedea F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:421-432. 10.1016/j.ijrobp.2007.12.024, 18325680.
10. Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 2004, 101:2011-2019. 10.1002/cncr.20608, 15452835.
11. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, Schroder FH, de Koning HJ. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005, 116:291-296. 10.1002/ijc.21043, 15800919.
12. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007, 109:2239-2247. 10.1002/cncr.22676, 17455209.
13. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004, 96:1358-1367. 10.1093/jnci/djh259, 15367568.
14. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261. 10.1056/NEJMoa074311, 18354103.
15. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905. 10.1016/S0090-4295(00)00858-X, 11113727.
16. Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010, 28:4687-4696. 10.1200/JCO.2009.25.3245, 20921463.
17. Katz A. CyberKnife radiosurgery for prostate cancer. Technol Cancer Res Treat 2010, 9:463-472.
18. Athanassiou H, Antonadou D, Coliarakis N, Kouveli A, Synodinou M, Paraskevaidis M, Sarris G, Georgakopoulos GR, Panousaki K, Karageorgis P, Throuvalas N. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003, 56:1154-1160. 10.1016/S0360-3016(03)00187-1, 12829154.
19. Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys 2008, 70:90-95. 10.1016/j.ijrobp.2007.05.057, 2267374, 17855015.
20. Ferrer M, Garin O, Pera J, Prats JM, Mendivil J, Alonso J, De Paula B, Herruzo I, Hervas A, Macias V, et al. Evaluation of the quality of life of patients with localizad prostate cancer: validation of the Spanish version of the EPIC. Med Clin (Barc) 2009, 132:128-135.
21. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41:582-592.
22. Twisk J, de Vente W. Attrition in longitudinal studies. How to deal with missing data. J Clin Epidemiol 2002, 55:329-337. 10.1016/S0895-4356(01)00476-0, 11927199.
23. Lepor H, Kaci L, Xue X. Continence following radical retropubic prostatectomy using self-reporting instruments. J Urol 2004, 171:1212-1215. 10.1097/01.ju.0000110631.81774.9c, 14767304.
24. Nandipati KC, Raina R, Agarwal A, Zippe CD. Nerve-sparing surgery significantly affects long-term continence after radical prostatectomy. Urology 2007, 70:1127-1130. 10.1016/j.urology.2007.07.042, 18158032.
25. Donnellan SM, Duncan HJ, MacGregor RJ, Russell JM. Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology 1997, 49:225-230. 10.1016/S0090-4295(96)00451-7, 9037284.
26. Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol 2007, 178:2385-2389. discussion 2389-2390, 10.1016/j.juro.2007.08.008, 17936849.
27. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82:228-234. 10.1016/j.ijrobp.2010.10.026, 21183287.
28. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for Low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:887-882.
29. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, Collins SP, Kaplan ID. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011, 118(15):3681-3690.
30. Patel VR, Coelho RF, Chauhan S, Orvieto MA, Palmer KJ, Rocco B, Sivaraman A, Coughlin G. Continence, potency and oncological outcomes after robotic-assisted radical prostatectomy: early trifecta results of a high-volume surgeon. BJU Int 2010, 106:696-702. 10.1111/j.1464-410X.2010.09541.x, 20707793.
31. Brandina R, Berger A, Kamoi K, Gill IS. Critical appraisal of robotic-assisted radical prostatectomy. Curr Opin Urol 2009, 19:290-296. 10.1097/MOU.0b013e328329a356, 19357511.
32. Hakimi AA, Blitstein J, Feder M, Shapiro E, Ghavamian R. Direct comparison of surgical and functional outcomes of robotic-assisted versus pure laparoscopic radical prostatectomy: single-surgeon experience. Urology 2009, 73:119-123. 10.1016/j.urology.2008.08.491, 18952268.
33. Singh I, Hemal AK. Robotic-assisted radical prostatectomy in 2010. Expert Rev Anticancer Ther 2010, 10:671-682. 10.1586/era.10.35, 20470000.
34. Rocco B, Matei DV, Melegari S, Ospina JC, Mazzoleni F, Errico G, Mastropasqua M, Santoro L, Detti S, de Cobelli O. Robotic vs open prostatectomy in a laparoscopically naive centre: a matched-pair analysis. BJU Int 2009, 104:991-995. 10.1111/j.1464-410X.2009.08532.x, 19426191.
35. Finkelstein J, Eckersberger E, Sadri H, Taneja SS, Lepor H, Djavan B. Open versus laparoscopic versus robot-assisted laparoscopic prostatectomy: the European and US experience. Rev Urol 2010, 12:35-43. 2859140, 20428292.
36. Levinson AW, Lavery HJ, Ward NT, Su LM, Pavlovich CP. Is a return to baseline sexual function possible? An analysis of sexual function outcomes following laparoscopic radical prostatectomy. World J Urol 2011, 29:29-34. 10.1007/s00345-010-0616-5, 21107844.
37. Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int 2012, 109:898-905. 10.1111/j.1464-410X.2011.10551.x, 21933328.
38. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010, 78:442-448. 10.1016/j.ijrobp.2009.07.1748, 20137864.
39. Echner GG, Kilby W, Lee M, Earnst E, Sayeh S, Schlaefer A, Rhein B, Dooley JR, Lang C, Blanck O, et al. The design, physical properties and clinical utility of an iris collimator for robotic radiosurgery. Phys Med Biol 2009, 54:5359-5380. 10.1088/0031-9155/54/18/001, 19687567.
40. Poll JJ, Hoogeman MS, Prevost JB, Nuyttens JJ, Levendag PC, Heijmen BJ. Reducing monitor units for robotic radiosurgery by optimized use of multiple collimators. Med Phys 2008, 35:2294-2299. 10.1118/1.2919090, 18649461.
41. Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010, 9:473-477.
42. Ham WS, Kim SW, Kim WT, Park SY, Choi YD. Robotic prostatectomy in patient with an abdominoperineal resection. J Laparoendosc Adv Surg Tech A 2009, 19:383-387. 10.1089/lap.2008.0110, 19061364.
43. Murphy DG, Kerger M, Crowe H, Peters JS, Costello AJ. Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. Eur Urol 2009, 55:1358-1366. 10.1016/j.eururo.2008.12.035, 19147274.
44. Boike TP, Lotan Y, Cho LC, Brindle J, Derose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, et al. Phase I dose-escalation study of stereotactic body radiation therapy for Low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29:2020-2026. 10.1200/JCO.2010.31.4377, 3138546, 21464418.
45. Kang JK, Cho CK, Choi CW, Yoo S, Kim MS, Yang K, Yoo H, Kim JH, Seo YS, Lee DH, Jo M. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011, 97:43-48.
46. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105. 10.1016/j.ijrobp.2006.10.050, 17336216.